Korean J Fam Med.  2025 May;46(3):127-136. 10.4082/kjfm.25.0080.

Systemic aging delay and anti-aging therapy using allogeneic stem cells

• Han S
• Kim SW

• KMID: 2568001
• DOI: http://doi.org/10.4082/kjfm.25.0080

Abstract

Allogeneic stem cells derived from umbilical cord tissue, placenta, and umbilical cord blood have shown potential in treating delayed systemic aging and aging-related diseases. Aging induces cellular senescence, oxidative stress, chronic inflammation, and stem cell depletion, all of which contribute to tissue damage and functional decline. Recent advances in regenerative medicine suggest that allogeneic stem cells can mitigate these aging processes through immunomodulation and tissue regeneration. In particular, umbilical cord-derived mesenchymal stem cells have gained attention for clinical applications owing to their strong immunomodulatory properties and low immunogenicity. These cells can repair damaged tissues and enhance metabolic and cognitive function by secreting various cytokines, growth factors, and exosomes, offering potential treatment for aging-related conditions such as osteoporosis and neurodegenerative disorders. Both clinical and preclinical studies indicate that allogeneic stem cells play a critical role in alleviating these diseases, including osteoporosis, osteoarthritis, cardiovascular diseases, and neurodegenerative disorders. Despite their therapeutic potential, challenges remain, such as immune compatibility, long-term safety, and the lack of standardized protocols for large-scale production. This review outlines the biological mechanisms by which allogeneic stem cells contribute to delayed aging, summarizes current clinical research, and explores future prospects. Allogeneic stem cells may offer novel strategies for delaying aging and extending lifespan.

Keyword

Allogeneic Transplantation; Anti-aging; Stem Cells; Mesenchymal Stem Cells; Umbilical Cord